Intellipharmaceutics Closes US$1.05 Million Convertible Debenture Financing with Drs. Isa and Amina Odidi May 7, 2019
U.S. FDA Acknowledges Receipt of Intellipharmaceutics' Resubmission of Oxycodone ER New Drug Application, Deems it a Complete Response, and Designates August 28, 2019 as Goal Date for Review Mar 29, 2019
Intellipharmaceutics Receives Nasdaq Listing Determination; To Begin Trading on the OTC Markets System Mar 19, 2019
Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER Mar 4, 2019
